299 related articles for article (PubMed ID: 11422108)
1. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N
Clin Endocrinol (Oxf); 2001 Jun; 54(6):739-50. PubMed ID: 11422108
[TBL] [Abstract][Full Text] [Related]
2. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
3. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
[TBL] [Abstract][Full Text] [Related]
4. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
5. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
6. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover.
Gürlek A; Gedik O
J Endocrinol Invest; 2001 Jun; 24(6):408-14. PubMed ID: 11434664
[TBL] [Abstract][Full Text] [Related]
7. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women.
Pereda CA; Hannon RA; Naylor KE; Eastell R
BJOG; 2002 Jul; 109(7):812-20. PubMed ID: 12135219
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
9. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
[TBL] [Abstract][Full Text] [Related]
10. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
Cooper C; Stakkestad JA; Radowicki S; Hardy P; Pilate C; Dain MP; Delmas PD
Osteoporos Int; 1999; 9(4):358-66. PubMed ID: 10550454
[TBL] [Abstract][Full Text] [Related]
11. Determinants of bone density in healthy older men with low testosterone levels.
Kenny AM; Prestwood KM; Marcello KM; Raisz LG
J Gerontol A Biol Sci Med Sci; 2000 Sep; 55(9):M492-7. PubMed ID: 10995046
[TBL] [Abstract][Full Text] [Related]
12. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
Guo CY; Jones TH; Eastell R
J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
14. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
16. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
17. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer.
Taxel P; Fall PM; Albertsen PC; Dowsett RD; Trahiotis M; Zimmerman J; Ohannessian C; Raisz LG
J Clin Endocrinol Metab; 2002 Nov; 87(11):4907-13. PubMed ID: 12414849
[TBL] [Abstract][Full Text] [Related]
18. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
19. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies.
Abrahamsen B; Hangaard J; Horn HC; Hansen TB; Gregersen G; Hansen-Nord M; Vahl N; Junker P; Andersen M; Hagen C
Clin Endocrinol (Oxf); 2002 Aug; 57(2):273-81. PubMed ID: 12153608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
